Drug Trial Radar · NCT04338022
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,124
Actual
Start
Jun 12, 2020
Primary completion
Oct 2, 2023
Study completion Mar 8, 2024
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- Collaborators
- EMD Serono Research & Development Institute, Inc.
- First posted
- Apr 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Conditions
- Relapsing Multiple Sclerosis
Interventions
TeriflunomideDrug
Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.
EvobrutinibDrug
Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)Time frame: From baseline to 172 weeks
- Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: From OLE Baseline (DBTP Week 96) to OLE Week 52
Locations
279 sites in 31 countries. Site status is shown where the registry gives one.
Research Site 629
Mobile, Alabama
Research Site 614
Phoenix, Arizona
Research Site 677
Phoenix, Arizona
Research Site 642
Long Beach, California
Research Site 644
Pasadena, California
Research Site 672
San Diego, California
Research Site 634
Stamford, Connecticut
Research Site 656
Washington D.C., District of Columbia
Research Site 616
Boca Raton, Florida
Research Site 625
Maitland, Florida
Research Site 617
Miami, Florida
Research Site 643
Ormond Beach, Florida
Research site 645
St. Petersburg, Florida
Research Site 652
Tallahassee, Florida
Research Site 621
Elk Grove Village, Illinois
Research Site 649
Northbrook, Illinois
Research Site 675
Peoria, Illinois
Research Site 628
Rolling Meadows, Illinois
Research Site 624
Indianapolis, Indiana
Research Site 632
Kansas City, Kansas
Research Site 653
New Orleans, Louisiana
Research Site 623
Baltimore, Maryland
Research Site 633
Boston, Massachusetts
Research Site 639
Foxborough, Massachusetts
Research Site 635
Lawrence, Massachusetts
Research Site 636
Worcester, Massachusetts
Research Site 613
Detroit, Michigan
Research Site 612
Farmington Hills, Michigan
Research Site 638
St Louis, Missouri
Research Site 664
St Louis, Missouri
Research Site 668
Omaha, Nebraska
Research Site 626
Las Vegas, Nevada
Research Site 667
Audubon, New Jersey
Research Site 620
Patchogue, New York
Research Site 663
Akron, Ohio
Research Site 630
Toledo, Ohio
Research Site 611
Oklahoma City, Oklahoma
Research Site 641
Oklahoma City, Oklahoma
Research Site 615
Springfield, Oregon
Research Site 647
Willow Grove, Pennsylvania
Showing 40 of 279 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.